查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1414926

免疫查核点抑制剂市场：按类型、按应用：2023-2032 年全球机会分析与产业预测

Immune Checkpoint Inhibitors Market By Type, By Application : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 248 Pages | 商品交期: 2-3个工作天内

价格

免疫查核点抑制剂（ICI）市场2022年估值为401亿美元，预计2023年至2032年复合年增长率为16.8%，到2032年达到1894亿美元。

免疫检查点抑制剂市场-IMG1

癌细胞利用这些查核点来逃避免疫系统的检测和破坏。免疫查核点抑制剂针对特定蛋白，如PD-1（程序性细胞死亡蛋白1）、PD-L1（程序性死亡配体1）和CTLA-4（细胞毒性T淋巴球相关蛋白4），以阻断发挥作用。透过抑制这些蛋白质，这些药物使免疫系统能够更有效地识别和对抗癌细胞。

推动免疫查核点抑制剂市场成长的主要因素是研发的进步、癌症患者数量的增加、临床试验数量的增加、研究计画的扩大、策略倡议以及新适应症的核准扩大。癌症仍然是全世界死亡的主要原因，并且诊断出患有各种癌症类型的病例数量持续增加。例如，根据美国美国癌症研究所癌症控制和人口科学部门 (DCCPS) 的数据，美国有 623,405 人患有转移性乳腺癌、前列腺癌、肺癌、大肠或转移性黑色素瘤。随着癌症负担的增加，迫切需要更有效的治疗方案，从而增加了对免疫查核点抑制剂的需求。

此外，越来越多的针对免疫查核点抑制剂的临床试验预计也将促进市场成长。製药公司、生技公司和学术机构越来越多地将资源投入临床研究。该投资旨在研究免疫查核点抑制剂在多种癌症类型中的安全性、有效性和可用性。这些临床试验的重点是探索新型药物组合、评估治疗反应和识别预测性生物标记物，为扩大我们对免疫主导疗法的理解做出了重大贡献。例如，2023 年 7 月，默克公司和 Moderna 公司宣布，他们的临床实验性个人化新抗原辅助性治疗（宣布启动结合V940 (mRNA-4157) 的关键3 期随机V940-001 临床试验，V940 (mRNA-4157 ) 是一种INT 药物） ），与默沙东的抗PD-1疗法KEYTRUDA合併使用。此类临床试验的结果不仅可以作为药物开拓的驱动力，还有助于确定治疗策略，进一步支持免疫查核点抑制剂市场的成长。

此外，製药公司、生技公司和学术机构之间的策略联盟已成为推动免疫查核点抑制剂市场成长的关键因素。伙伴关係和联盟促进专业知识、资源和技术的整合，以加快药物研发和开发过程。例如，2020年5月，全球生物製药公司信达生物与德克萨斯大学MD安德森癌症中心宣布推出信达生物抗PD-1单株抗体达伯舒（信迪利单抗注射液），使用于治疗罕见癌症我们宣布，我们已签订战略合作伙伴协议，在美国共同开发该药物。透过此类合作研究，我们已成功开发并商业化了多种免疫查核点抑制剂，扩大了免疫查核点抑制剂在癌症领域的应用范围。

目录

第一章简介

第 2 章执行摘要

第三章市场概况

  • 市场定义和范围
  • 主要发现
    • 影响因素
    • 主要投资机会
  • 波特五力分析
  • 市场动态
    • 促进因素
      • 全球癌症发生率增加
      • 老年人口增加
      • 免疫查核点抑制剂支持报销政策
    • 抑制因素
      • 免疫查核点抑制剂价格高
    • 机会
      • 管道药物增加
      • 新兴市场的成长机会

第四章免疫查核点抑制剂市场：依类型

  • 概述
  • CTLA-4抑制剂
  • PD-1抑制剂
  • PD-L1抑制剂

第五章免疫查核点抑制剂市场：依应用分类

  • 概述
  • 肺癌
  • 膀胱癌
  • 黑色素瘤
  • 大肠
  • 霍奇金淋巴瘤
  • 其他的

第六章免疫查核点抑制剂市场：按地区

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 其他的
  • 拉丁美洲/中东/非洲
    • 巴西
    • 其他的

第七章 竞争形势

  • 介绍
  • 关键成功策略
  • 10家主要企业产品图谱
  • 竞争对手仪表板
  • 竞争热图
  • 主要企业定位（2022年）

第八章 公司简介

  • Merck & Co., Inc.
  • AstraZeneca plc
  • F. Hoffmann-La Roche Ltd.
  • Merck KGaA
  • Regeneron Pharmaceuticals, Inc.
  • Bristol-Myers Squibb Company
  • BeiGene, Ltd.
  • Shanghai Junshi Biosciences Co., Ltd.
  • GlaxoSmithKline plc
  • Innovent Biologics, Inc.
Product Code: A03382

According to a new report published by Allied Market Research, titled, "Immune Checkpoint Inhibitors Market," The immune checkpoint inhibitors market was valued at $40.1 billion in 2022, and is estimated to reach $189.4 billion by 2032, growing at a CAGR of 16.8% from 2023 to 2032.

Immune Checkpoint Inhibitors Market - IMG1

Cancer cells exploit these checkpoints to evade the immune system's detection and destruction. Immune checkpoint inhibitors work by targeting and blocking specific proteins, such as PD-1 (programmed cell death protein 1), PD-L1 (programmed death-ligand 1), or CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), which are involved in these checkpoints. By inhibiting these proteins, these drugs enable the immune system to more effectively identify and combat cancer cells.

The major factors driving the growth of immune checkpoint inhibitors market are advancements in R&D, increase in prevalence of cancer cases, increase in number of clinical trials, expanding research initiatives, strategic collaborations, and growing approvals for new indications. Cancer remains a leading cause of mortality globally, with continuous rise in diagnosed cases across various cancer types. For instance, National Cancer Institute, Division of Cancer Control & Population Sciences (DCCPS), stated that, 623,405 people are living with metastatic breast, prostate, lung, colorectal cancer, or metastatic melanoma in the U.S. As the burden of cancer grows, there is a pressing need for more effective treatment options, leading to the heightened demand for immune checkpoint inhibitors.

Further, increase in the number of clinical trials focusing on the immune checkpoint inhibitors is expected to fuel the market growth. There is a growing inclination among pharmaceutical companies, biotechnology firms, and academic institutions to allocate more resources toward clinical research. This investment aims to scrutinize the safety, effectiveness, and possible uses of immune checkpoint inhibitors across diverse cancer types. These trials, focused on investigating novel drug combinations, evaluating treatment reactions, and pinpointing predictive biomarkers, significantly contribute to broadening the comprehension of immune-driven treatments. For instance, in July 2023, Merck & Co., Inc., and Moderna, Inc. announced the initiation of the pivotal Phase 3 randomized V940-001 clinical trial evaluating V940 (mRNA-4157), an investigational individualized neoantigen therapy (INT), in combination with KEYTRUDA, Merck's anti-PD-1 therapy, as an adjuvant treatment in patients with resected high-risk (Stage IIB-IV) melanoma. The results from these trials not only drive drug development but also inform treatment decisions, further boosting the growth of the immune checkpoint inhibitors market.

Furthermore, strategic collaborations among pharmaceutical companies, biotechnology firms, and academic institutions have emerged as a key factor propelling the growth of the immune checkpoint inhibitors market. Partnerships and alliances facilitate the consolidation of expertise, resources, and technologies, expediting the drug discovery and development process. For instance, in May 2020, Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of cancer, autoimmune, metabolic & other major diseases, and The University of Texas MD Anderson Cancer Center, announced a strategic collaboration agreement to co-develop TYVYT (sintilimab injection), Innovent's anti-PD-1 monoclonal antibody, for treating rare cancers in the U.S. In addition, collaborative efforts facilitate the exploration of diverse therapeutic applications, the conduct of larger clinical trials, and the accelerated translation of research findings into clinical applications. Such collaborations have led to the successful development and commercialization of several immune checkpoint inhibitors, widening their reach and applications in oncology.

The immune checkpoint inhibitors market is segmented on the basis of product type, application, and region. By product type, the market is categorized into CTLA-4 inhibitor, PD-1 inhibitor, and PD-L1 inhibitor. On the basis of application, the market is classified into lung cancer, bladder cancer, melanoma, colorectal cancer, Hodgkin lymphoma, and others. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, and rest of LAMEA).

Major key players that operate in the global immune checkpoint inhibitors market are Merck & Co., Inc., AstraZeneca plc, F. Hoffmann-La Roche Ltd., Merck KGaA, Regeneron Pharmaceuticals, Inc., Bristol-Myers Squibb Company, BeiGene, Ltd., Shanghai Junshi Biosciences Co., Ltd., GlaxoSmithKline plc, and Innovent Biologics, Inc. The key players have adopted strategies such as acquisition, agreement, strategic alliance, collaboration, clinical trial, expansion, joint venture, new product development, and product approval to expand their product portfolio.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the immune checkpoint inhibitors market analysis from 2022 to 2032 to identify the prevailing immune checkpoint inhibitors market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the immune checkpoint inhibitors market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global immune checkpoint inhibitors market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Type

  • CTLA-4 inhibitor
  • PD-1 inhibitor
  • PD-L1 inhibitor

By Application

  • Lung Cancer
  • Bladder Cancer
  • Melanoma
  • Colorectal Cancer
  • Hodgkin lymphoma
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Rest of LAMEA

Key Market Players:

    • Merck & Co., Inc.
    • AstraZeneca plc
    • Merck KGaA
    • Bristol-Myers Squibb Company
    • BeiGene, Ltd.
    • Shanghai Junshi Biosciences Co., Ltd.
    • GlaxoSmithKline plc
    • Innovent Biologics, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Regeneron Pharmaceuticals, Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. High bargaining power of suppliers
    • 3.3.2. Moderate threat of new entrants
    • 3.3.3. Low threat of substitutes
    • 3.3.4. Low intensity of rivalry
    • 3.3.5. High bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Increase in incidences of cancer across the globe
      • 3.4.1.2. Rise in geriatric population
      • 3.4.1.3. Supportive reimbursement policies for immune checkpoint inhibitors
    • 3.4.2. Restraints
      • 3.4.2.1. Higher cost of immune checkpoint inhibitors
    • 3.4.3. Opportunities
      • 3.4.3.1. Increase in number of pipeline drugs
      • 3.4.3.2. Growth opportunities in emerging markets

CHAPTER 4: IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. CTLA-4 inhibitor
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. PD-1 inhibitor
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. PD-L1 inhibitor
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country

CHAPTER 5: IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Lung Cancer
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Bladder Cancer
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Melanoma
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country
  • 5.5. Colorectal Cancer
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by region
    • 5.5.3. Market share analysis by country
  • 5.6. Hodgkin lymphoma
    • 5.6.1. Key market trends, growth factors and opportunities
    • 5.6.2. Market size and forecast, by region
    • 5.6.3. Market share analysis by country
  • 5.7. Others
    • 5.7.1. Key market trends, growth factors and opportunities
    • 5.7.2. Market size and forecast, by region
    • 5.7.3. Market share analysis by country

CHAPTER 6: IMMUNE CHECKPOINT INHIBITORS MARKET, BY REGION

  • 6.1. Overview
    • 6.1.1. Market size and forecast By Region
  • 6.2. North America
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by Type
    • 6.2.3. Market size and forecast, by Application
    • 6.2.4. Market size and forecast, by country
      • 6.2.4.1. U.S.
      • 6.2.4.1.1. Market size and forecast, by Type
      • 6.2.4.1.2. Market size and forecast, by Application
      • 6.2.4.2. Canada
      • 6.2.4.2.1. Market size and forecast, by Type
      • 6.2.4.2.2. Market size and forecast, by Application
      • 6.2.4.3. Mexico
      • 6.2.4.3.1. Market size and forecast, by Type
      • 6.2.4.3.2. Market size and forecast, by Application
  • 6.3. Europe
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by Type
    • 6.3.3. Market size and forecast, by Application
    • 6.3.4. Market size and forecast, by country
      • 6.3.4.1. Germany
      • 6.3.4.1.1. Market size and forecast, by Type
      • 6.3.4.1.2. Market size and forecast, by Application
      • 6.3.4.2. France
      • 6.3.4.2.1. Market size and forecast, by Type
      • 6.3.4.2.2. Market size and forecast, by Application
      • 6.3.4.3. UK
      • 6.3.4.3.1. Market size and forecast, by Type
      • 6.3.4.3.2. Market size and forecast, by Application
      • 6.3.4.4. Rest of Europe
      • 6.3.4.4.1. Market size and forecast, by Type
      • 6.3.4.4.2. Market size and forecast, by Application
  • 6.4. Asia-Pacific
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by Type
    • 6.4.3. Market size and forecast, by Application
    • 6.4.4. Market size and forecast, by country
      • 6.4.4.1. Japan
      • 6.4.4.1.1. Market size and forecast, by Type
      • 6.4.4.1.2. Market size and forecast, by Application
      • 6.4.4.2. China
      • 6.4.4.2.1. Market size and forecast, by Type
      • 6.4.4.2.2. Market size and forecast, by Application
      • 6.4.4.3. India
      • 6.4.4.3.1. Market size and forecast, by Type
      • 6.4.4.3.2. Market size and forecast, by Application
      • 6.4.4.4. Australia
      • 6.4.4.4.1. Market size and forecast, by Type
      • 6.4.4.4.2. Market size and forecast, by Application
      • 6.4.4.5. South Korea
      • 6.4.4.5.1. Market size and forecast, by Type
      • 6.4.4.5.2. Market size and forecast, by Application
      • 6.4.4.6. Rest of Asia-Pacific
      • 6.4.4.6.1. Market size and forecast, by Type
      • 6.4.4.6.2. Market size and forecast, by Application
  • 6.5. LAMEA
    • 6.5.1. Key market trends, growth factors and opportunities
    • 6.5.2. Market size and forecast, by Type
    • 6.5.3. Market size and forecast, by Application
    • 6.5.4. Market size and forecast, by country
      • 6.5.4.1. Brazil
      • 6.5.4.1.1. Market size and forecast, by Type
      • 6.5.4.1.2. Market size and forecast, by Application
      • 6.5.4.2. Rest of LAMEA
      • 6.5.4.2.1. Market size and forecast, by Type
      • 6.5.4.2.2. Market size and forecast, by Application

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top winning strategies
  • 7.3. Product mapping of top 10 player
  • 7.4. Competitive dashboard
  • 7.5. Competitive heatmap
  • 7.6. Top player positioning, 2022

CHAPTER 8: COMPANY PROFILES

  • 8.1. Merck & Co., Inc.
    • 8.1.1. Company overview
    • 8.1.2. Key executives
    • 8.1.3. Company snapshot
    • 8.1.4. Operating business segments
    • 8.1.5. Product portfolio
    • 8.1.6. Business performance
    • 8.1.7. Key strategic moves and developments
  • 8.2. AstraZeneca plc
    • 8.2.1. Company overview
    • 8.2.2. Key executives
    • 8.2.3. Company snapshot
    • 8.2.4. Operating business segments
    • 8.2.5. Product portfolio
    • 8.2.6. Business performance
    • 8.2.7. Key strategic moves and developments
  • 8.3. F. Hoffmann-La Roche Ltd.
    • 8.3.1. Company overview
    • 8.3.2. Key executives
    • 8.3.3. Company snapshot
    • 8.3.4. Operating business segments
    • 8.3.5. Product portfolio
    • 8.3.6. Business performance
    • 8.3.7. Key strategic moves and developments
  • 8.4. Merck KGaA
    • 8.4.1. Company overview
    • 8.4.2. Key executives
    • 8.4.3. Company snapshot
    • 8.4.4. Operating business segments
    • 8.4.5. Product portfolio
    • 8.4.6. Business performance
    • 8.4.7. Key strategic moves and developments
  • 8.5. Regeneron Pharmaceuticals, Inc.
    • 8.5.1. Company overview
    • 8.5.2. Key executives
    • 8.5.3. Company snapshot
    • 8.5.4. Operating business segments
    • 8.5.5. Product portfolio
    • 8.5.6. Business performance
    • 8.5.7. Key strategic moves and developments
  • 8.6. Bristol-Myers Squibb Company
    • 8.6.1. Company overview
    • 8.6.2. Key executives
    • 8.6.3. Company snapshot
    • 8.6.4. Operating business segments
    • 8.6.5. Product portfolio
    • 8.6.6. Business performance
    • 8.6.7. Key strategic moves and developments
  • 8.7. BeiGene, Ltd.
    • 8.7.1. Company overview
    • 8.7.2. Key executives
    • 8.7.3. Company snapshot
    • 8.7.4. Operating business segments
    • 8.7.5. Product portfolio
    • 8.7.6. Business performance
    • 8.7.7. Key strategic moves and developments
  • 8.8. Shanghai Junshi Biosciences Co., Ltd.
    • 8.8.1. Company overview
    • 8.8.2. Key executives
    • 8.8.3. Company snapshot
    • 8.8.4. Operating business segments
    • 8.8.5. Product portfolio
    • 8.8.6. Business performance
    • 8.8.7. Key strategic moves and developments
  • 8.9. GlaxoSmithKline plc
    • 8.9.1. Company overview
    • 8.9.2. Key executives
    • 8.9.3. Company snapshot
    • 8.9.4. Operating business segments
    • 8.9.5. Product portfolio
    • 8.9.6. Business performance
    • 8.9.7. Key strategic moves and developments
  • 8.10. Innovent Biologics, Inc.
    • 8.10.1. Company overview
    • 8.10.2. Key executives
    • 8.10.3. Company snapshot
    • 8.10.4. Operating business segments
    • 8.10.5. Product portfolio
    • 8.10.6. Business performance
    • 8.10.7. Key strategic moves and developments

LIST OF TABLES

  • TABLE 01. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 02. IMMUNE CHECKPOINT INHIBITORS MARKET FOR CTLA-4 INHIBITOR, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. IMMUNE CHECKPOINT INHIBITORS MARKET FOR PD-1 INHIBITOR, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. IMMUNE CHECKPOINT INHIBITORS MARKET FOR PD-L1 INHIBITOR, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 06. IMMUNE CHECKPOINT INHIBITORS MARKET FOR LUNG CANCER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. IMMUNE CHECKPOINT INHIBITORS MARKET FOR BLADDER CANCER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. IMMUNE CHECKPOINT INHIBITORS MARKET FOR MELANOMA, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. IMMUNE CHECKPOINT INHIBITORS MARKET FOR COLORECTAL CANCER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. IMMUNE CHECKPOINT INHIBITORS MARKET FOR HODGKIN LYMPHOMA, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. IMMUNE CHECKPOINT INHIBITORS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. IMMUNE CHECKPOINT INHIBITORS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 14. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 16. U.S. IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 17. U.S. IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 18. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 19. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 20. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 21. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 22. EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 23. EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 24. EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 25. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 26. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 27. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 28. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 29. UK IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 30. UK IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 31. REST OF EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 32. REST OF EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 33. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 34. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 35. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 36. JAPAN IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 37. JAPAN IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 38. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 39. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 40. INDIA IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 41. INDIA IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 42. AUSTRALIA IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 43. AUSTRALIA IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 44. SOUTH KOREA IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 45. SOUTH KOREA IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 46. REST OF ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 47. REST OF ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 48. LAMEA IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 49. LAMEA IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 50. LAMEA IMMUNE CHECKPOINT INHIBITORS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 51. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 52. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 53. REST OF LAMEA IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 54. REST OF LAMEA IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 55. MERCK & CO., INC.: KEY EXECUTIVES
  • TABLE 56. MERCK & CO., INC.: COMPANY SNAPSHOT
  • TABLE 57. MERCK & CO., INC.: PRODUCT SEGMENTS
  • TABLE 58. MERCK & CO., INC.: PRODUCT PORTFOLIO
  • TABLE 59. MERCK & CO., INC.: KEY STRATERGIES
  • TABLE 60. ASTRAZENECA PLC: KEY EXECUTIVES
  • TABLE 61. ASTRAZENECA PLC: COMPANY SNAPSHOT
  • TABLE 62. ASTRAZENECA PLC: PRODUCT SEGMENTS
  • TABLE 63. ASTRAZENECA PLC: PRODUCT PORTFOLIO
  • TABLE 64. ASTRAZENECA PLC: KEY STRATERGIES
  • TABLE 65. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 66. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 67. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
  • TABLE 68. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
  • TABLE 69. F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES
  • TABLE 70. MERCK KGAA: KEY EXECUTIVES
  • TABLE 71. MERCK KGAA: COMPANY SNAPSHOT
  • TABLE 72. MERCK KGAA: PRODUCT SEGMENTS
  • TABLE 73. MERCK KGAA: PRODUCT PORTFOLIO
  • TABLE 74. MERCK KGAA: KEY STRATERGIES
  • TABLE 75. REGENERON PHARMACEUTICALS, INC.: KEY EXECUTIVES
  • TABLE 76. REGENERON PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
  • TABLE 77. REGENERON PHARMACEUTICALS, INC.: PRODUCT SEGMENTS
  • TABLE 78. REGENERON PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
  • TABLE 79. REGENERON PHARMACEUTICALS, INC.: KEY STRATERGIES
  • TABLE 80. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES
  • TABLE 81. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
  • TABLE 82. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT SEGMENTS
  • TABLE 83. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
  • TABLE 84. BRISTOL-MYERS SQUIBB COMPANY: KEY STRATERGIES
  • TABLE 85. BEIGENE, LTD.: KEY EXECUTIVES
  • TABLE 86. BEIGENE, LTD.: COMPANY SNAPSHOT
  • TABLE 87. BEIGENE, LTD.: PRODUCT SEGMENTS
  • TABLE 88. BEIGENE, LTD.: PRODUCT PORTFOLIO
  • TABLE 89. BEIGENE, LTD.: KEY STRATERGIES
  • TABLE 90. SHANGHAI JUNSHI BIOSCIENCES CO., LTD.: KEY EXECUTIVES
  • TABLE 91. SHANGHAI JUNSHI BIOSCIENCES CO., LTD.: COMPANY SNAPSHOT
  • TABLE 92. SHANGHAI JUNSHI BIOSCIENCES CO., LTD.: PRODUCT SEGMENTS
  • TABLE 93. SHANGHAI JUNSHI BIOSCIENCES CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 94. SHANGHAI JUNSHI BIOSCIENCES CO., LTD.: KEY STRATERGIES
  • TABLE 95. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
  • TABLE 96. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 97. GLAXOSMITHKLINE PLC: PRODUCT SEGMENTS
  • TABLE 98. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 99. GLAXOSMITHKLINE PLC: KEY STRATERGIES
  • TABLE 100. INNOVENT BIOLOGICS, INC.: KEY EXECUTIVES
  • TABLE 101. INNOVENT BIOLOGICS, INC.: COMPANY SNAPSHOT
  • TABLE 102. INNOVENT BIOLOGICS, INC.: PRODUCT SEGMENTS
  • TABLE 103. INNOVENT BIOLOGICS, INC.: PRODUCT PORTFOLIO
  • TABLE 104. INNOVENT BIOLOGICS, INC.: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. IMMUNE CHECKPOINT INHIBITORS MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF IMMUNE CHECKPOINT INHIBITORS MARKET,2022-2032
  • FIGURE 03. TOP IMPACTING FACTORS IN IMMUNE CHECKPOINT INHIBITORS MARKET (2022 TO 2032)
  • FIGURE 04. TOP INVESTMENT POCKETS IN IMMUNE CHECKPOINT INHIBITORS MARKET (2023-2032)
  • FIGURE 05. HIGH BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 07. LOW THREAT OF SUBSTITUTES
  • FIGURE 08. LOW INTENSITY OF RIVALRY
  • FIGURE 09. HIGH BARGAINING POWER OF BUYERS
  • FIGURE 10. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF IMMUNE CHECKPOINT INHIBITORS MARKET FOR CTLA-4 INHIBITOR, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF IMMUNE CHECKPOINT INHIBITORS MARKET FOR PD-1 INHIBITOR, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF IMMUNE CHECKPOINT INHIBITORS MARKET FOR PD-L1 INHIBITOR, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF IMMUNE CHECKPOINT INHIBITORS MARKET FOR LUNG CANCER, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF IMMUNE CHECKPOINT INHIBITORS MARKET FOR BLADDER CANCER, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF IMMUNE CHECKPOINT INHIBITORS MARKET FOR MELANOMA, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF IMMUNE CHECKPOINT INHIBITORS MARKET FOR COLORECTAL CANCER, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF IMMUNE CHECKPOINT INHIBITORS MARKET FOR HODGKIN LYMPHOMA, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF IMMUNE CHECKPOINT INHIBITORS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 22. IMMUNE CHECKPOINT INHIBITORS MARKET BY REGION, 2022 AND 2032(%)
  • FIGURE 23. U.S. IMMUNE CHECKPOINT INHIBITORS MARKET, 2022-2032 ($MILLION)
  • FIGURE 24. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET, 2022-2032 ($MILLION)
  • FIGURE 25. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. UK IMMUNE CHECKPOINT INHIBITORS MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. REST OF EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. JAPAN IMMUNE CHECKPOINT INHIBITORS MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. INDIA IMMUNE CHECKPOINT INHIBITORS MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. AUSTRALIA IMMUNE CHECKPOINT INHIBITORS MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. SOUTH KOREA IMMUNE CHECKPOINT INHIBITORS MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. REST OF ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. REST OF LAMEA IMMUNE CHECKPOINT INHIBITORS MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. TOP WINNING STRATEGIES, BY YEAR (2019-2023)
  • FIGURE 39. TOP WINNING STRATEGIES, BY DEVELOPMENT (2019-2023)
  • FIGURE 40. TOP WINNING STRATEGIES, BY COMPANY (2019-2023)
  • FIGURE 41. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 42. COMPETITIVE DASHBOARD
  • FIGURE 43. COMPETITIVE HEATMAP: IMMUNE CHECKPOINT INHIBITORS MARKET
  • FIGURE 44. TOP PLAYER POSITIONING, 2022
  • FIGURE 45. MERCK & CO., INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 46. MERCK & CO., INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 47. MERCK & CO., INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 48. ASTRAZENECA PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 49. ASTRAZENECA PLC: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 50. F. HOFFMANN-LA ROCHE LTD.: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 51. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 52. MERCK KGAA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 53. MERCK KGAA: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 54. MERCK KGAA: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 55. REGENERON PHARMACEUTICALS, INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 56. BRISTOL-MYERS SQUIBB COMPANY: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 57. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 58. BEIGENE, LTD.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 59. BEIGENE, LTD.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 60. SHANGHAI JUNSHI BIOSCIENCES CO., LTD.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 61. GLAXOSMITHKLINE PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 62. GLAXOSMITHKLINE PLC: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 63. GLAXOSMITHKLINE PLC: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 64. INNOVENT BIOLOGICS, INC.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 65. INNOVENT BIOLOGICS, INC.: REVENUE SHARE BY REGION, 2021 (%)